5α還原酶藥物Finasteride及Dutasteride與攝護腺癌的相關性
莊毓峰、謝肇新、許兆畬、歐宴泉、童敏哲1、張佑剛2
童綜合醫院 外科部泌尿科1，醫學研究部2
Association of Prostate cancer with 5-alpha reductase as Finasteride and Dutasteride.
Yu-Feng Chuang, Siu-San Tse, Jow-Yu Sheu, Yen-Chuan Ou, Min-Che Tung1, Yu-Kang Chang2
Divisions of Urology1, Department of Surgery, and Department of Medical Reserch2,
Tungs’ Taichung Metro Harbor Hospital, Taichung, Taiwan
Purpose: We investigate the potential association of Prostate cancer with 5-alpha reductase as Finasteride and Dutasteride in Taiwanese.
Materials and Methods: We research National Health Insurance Research Database (NHIRD), which contains registration files and claims data for NHI beneficiaries. In the present study, we examined data for 1 million NHI beneficiaries randomly sampled from the larger NHIRD. Total 7170 patients with Finasteride and Dutasteride treatment were included and separated to three groups as Finasteride group, Dutasteride group and both drugs group. Study subjects were considered to have prostate cancer if they had at least 2 ambulatory visits and 1 hospitalization with the diagnosis.
Results: In this research, χ2 tests were used to describe the differences between the Finasteride group and Dutasteride group (HR 1.90; 95% CI, 1.27-2.86) (p=0.0397). We also use Cox proportional hazards regression to determine the adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) of Dutasteride group compared to the Finasteride group (aHRs 1.04; 95% CI, 1.03-1.05)(p<0.001).
Conclusions: We cannot assess relationship between 5ARIs and different prostate cancer stage rate due to NHIRD data limitation. But the preliminary data showed Dutasteride possibly has association with higher incidence rate of prostate cancer with all stage than Finasteride. More excluding criteria and limitations should take into consideration for further study.